Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications
Open Access
- 1 November 2006
- journal article
- other
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 20 (11) , 2965-2975
Abstract
Several molecular aberrations have been implicated in the pathogenesis of pituitary tumors, but few have proven thus far to be of therapeutic value. Pituitary tumor-derived fibroblast growth factor receptor-4 (ptd-FGFR4) is an alternatively transcribed cytoplasmic isoform lacking most of the extracellular domain. This oncogene recapitulates the morphological features of human pituitary tumors in transgenic mice. To investigate the therapeutic potential of targeting ptd-FGFR4, we examined the impact of FGFR4 tyrosine kinase inhibition in xenografted mice. GH4 pituitary cells expressing ptd-FGFR4 develop into invasive tumors. Systemic treatment of mice bearing ptd-FGFR4 tumors with the FGFR-selective inhibitor PD173074 resulted in recovery of membranous N-cadherin staining and a significant reduction in tumor volume with less invasive growth behavior. Mutation of tyrosine Y754F in ptd-FGFR4 abrogated the effect of PD173074-mediated inhibition. The pivotal role of N-cadherin as a mediator of this pituitary cell growth was demonstrated by small interfering RNA mediated down-regulation, which promoted invasive growth in xenografted mice. To validate this model in primary human pituitary tumors, we examined the expression of ptd-FGFR4, N-cadherin, and clinical behavior. Loss of membranous N-cadherin correlated with cytoplasmic FGFR4 expression and with tumor invasiveness in surgically resected human pituitary tumors. Primary human pituitary tumor cells treated with PD173074 showed restoration of N-cadherin to the membrane with dephosphorylation of retinoblastoma protein. These data highlight the pathogenetic significance of N-cadherin misexpression and emphasize the importance of FGFR partnership in mediating its functions.Keywords
This publication has 28 references indexed in Scilit:
- Evolution of the Fgf and Fgfr gene familiesTrends in Genetics, 2004
- Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalkProceedings of the National Academy of Sciences, 2003
- The pathogenesis of pituitary tumoursNature Reviews Cancer, 2002
- Targeted expression of a human pituitary tumor–derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesisJournal of Clinical Investigation, 2002
- The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone ProductionMolecular Endocrinology, 2001
- Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesisNature Medicine, 1999
- Multistep signaling requirements for pituitary organogenesis in vivoGenes & Development, 1998
- Soluble dominant‐negative receptor uncovers essential roles for fibroblast growth factors in multi‐organ induction and patterningThe EMBO Journal, 1998
- Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary AdenomasThe Journal of Clinical Endocrinology & Metabolism, 1997
- Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.Proceedings of the National Academy of Sciences, 1989